Stockholders' Equity (Tables)
|
6 Months Ended |
Jun. 30, 2022 |
|---|
| Equity [Abstract] |
|
| Schedule of Shares Reserved for Future Issuance |
The Company has reserved shares of common stock for future issuances as follows: | | | | | | | | | | | | | June 30, | | December 31, | | 2022 | | 2021 | Common stock options issued and outstanding | 2,600,237 | | | 2,145,131 | | | Common stock restricted stock units issued and outstanding | 1,091,957 | | | 442,428 | | Common stock available for future grants | 3,838,605 | | | 3,751,115 | | | Common stock available for ESPP | 1,255,773 | | | 932,458 | | | Total | 8,786,572 | | | 7,271,132 | |
|
| Schedule of Summary of Stock Option Activity |
A summary of stock option activity for the six months ended June 30, 2022 is set forth below: | | | | | | | | | | | | | Outstanding Options | | Number of Shares | | Weighted Average Exercise Price | Balance, January 1, 2022 | 2,145,131 | | | $ | 13.44 | | Options granted | 655,200 | | | 26.56 | | Options exercised | (172,886) | | | 2.15 | | Options canceled | (27,208) | | | 19.96 | | Balance, June 30, 2022 | 2,600,237 | | | $ | 17.43 | |
|
| Schedule of Options Vested and Expected to Vest |
| | | | | | | | | | | | | | | | | | | June 30, 2022 | | Number of Shares | | Weighted Average Exercise Price | | Weighted Average Contractual Life (in Years) | | Options vested | 904,464 | | $ | 11.56 | | | 7.30 | | Options vested and expected to vest | 2,600,237 | | $ | 17.43 | | | 8.26 |
|
| Schedule of Activity with Respect to Restricted Stock Units |
Activity with respect to restricted stock units was as follows: | | | | | | | | | | | | | Number of Shares Underlying Outstanding Restricted Stock | | Weighted Average Grant Date Fair Value | | Unvested, January 1, 2022 | 442,428 | | | $ | 42.36 | | | Granted | 799,320 | | | 25.47 | | Vested | (115,380) | | | 37.64 | | Canceled | (34,411) | | | 33.22 | | | Unvested, June 30, 2022 | 1,091,957 | | | $ | 30.78 | |
|
| Schedule of Total Stock-Based Compensation |
Stock-based compensation expense is reflected in the statements of operations and comprehensive loss as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2022 | | 2021 | | 2022 | | 2021 | | Cost of goods sold | $ | 189 | | | $ | 120 | | | $ | 336 | | | $ | 210 | | | Research and development | 556 | | | 288 | | | 977 | | | 606 | | | Selling, general and administrative | 3,638 | | | 1,904 | | | 6,583 | | | 3,764 | | | Total | $ | 4,383 | | | $ | 2,312 | | | $ | 7,896 | | | $ | 4,580 | |
The above stock-based compensation expense related to the following equity-based awards (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2022 | | 2021 | | 2022 | | 2021 | | Stock options and restricted stock units | $ | 4,209 | | | $ | 1,520 | | | $ | 7,521 | | | $ | 2,559 | | | ESPP | 174 | | | 792 | | | 375 | | | 2,021 | | | Total | $ | 4,383 | | | $ | 2,312 | | | $ | 7,896 | | | $ | 4,580 | |
|